Rabbit Polyclonal GRIA1 Antibody

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Rat brain tissue and Mouse brain tissue lysates, Primary antibody: P04152(GRIA1 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P04152(GRIA1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04152(GRIA1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The GRIA1 antibody targets the glutamate ionotropic receptor AMPA type subunit 1 (GluA1), a critical component of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. These ligand-gated ion channels mediate the majority of fast excitatory synaptic transmission in the central nervous system. GluA1. encoded by the GRIA1 gene, forms tetrameric complexes with other AMPA receptor subunits (GluA2-4) to regulate synaptic plasticity, learning, and memory. Its function is modulated by post-translational modifications, trafficking, and interactions with scaffolding proteins.

GRIA1 antibodies are widely used in neuroscience research to study GluA1 expression, localization, and dynamics in neuronal tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding investigations into synaptic strength, long-term potentiation (LTP), and neurological disorders. Dysregulation of GluA1 has been implicated in conditions such as Alzheimer’s disease, epilepsy, and schizophrenia, making these antibodies valuable for mechanistic and diagnostic studies. Specific GRIA1 antibodies are validated for species reactivity (e.g., human, mouse, rat) and application-specific performance. Researchers also utilize them to explore therapeutic targets, as AMPA receptor modulation holds potential for treating cognitive deficits and neurodegenerative diseases. Proper controls, including knockout validation, are essential to ensure antibody specificity given structural similarities among AMPA receptor subunits.